Paper Details

  1. Home
  2. Paper Details

Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Author: AhmedAmina, BelknapRobert, BurgosMarcos, CohnDavid L, CraneCharles M, HorsburghC Robert, LoBuePhilip, MenziesDick, NjieGibril, RevesRandall, SterlingTimothy R, WinstonCarla A, ZennerDominik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

These updated guidelines recommend three preferred rifamycin-based regimens and two alternative monotherapy regimens for treating latent tuberculosis infection (LTBI) in the United States. The preferred regimens are 3 months of once-weekly isoniazid plus rifapentine, 4 months of daily rifampin, or 3 months of daily isoniazid plus rifampin. The two alternative regimens are daily isoniazid for 6 or 9 months. The shorter rifamycin-based regimens are preferred due to their effectiveness, safety, and higher treatment completion rates.
Paper Details　
Original Abstract of the Article :
Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041302/

データ提供：米国国立医学図書館（NLM）

Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC

In the vast desert of infectious diseases, tuberculosis (TB) remains a significant public health concern. This study, akin to a camel caravan navigating a treacherous path to find a cure, presents updated guidelines for the treatment of latent TB infection (LTBI). The authors, a team of experts from the National Tuberculosis Controllers Association (NTCA) and the Centers for Disease Control and Prevention (CDC), reviewed current evidence and formulated recommendations for the most effective and safe treatment regimens for LTBI.

Treatment Guidelines for Latent TB Infection: A Roadmap to Prevention

The study provides a comprehensive overview of treatment options for LTBI, including preferred and alternative regimens. The authors recommend shorter-course rifamycin-based treatments over longer-course isoniazid monotherapy due to their greater effectiveness and safety. This finding, like a well-stocked oasis in the desert, offers a promising path to preventing active TB disease. The study also emphasizes the importance of completing treatment courses to ensure successful outcomes.

Tuberculosis Prevention: A Collective Effort

This study highlights the importance of effective treatment guidelines for preventing active TB disease. The recommendations, like a well-marked camel trail, provide guidance for healthcare professionals and public health officials to effectively manage and prevent TB. The study emphasizes the need for a collaborative approach to TB control, involving individuals, healthcare providers, and public health agencies.

Dr.Camel's Conclusion

This study presents updated guidelines for the treatment of latent tuberculosis infection. The recommendations, like a well-equipped camel caravan, provide a clear roadmap for managing this public health concern. The study emphasizes the importance of effective treatment regimens, adherence to treatment, and a collaborative approach to TB control. The findings underscore the need for continuous research and innovation to combat this persistent threat.

Date :
  1. Date Completed 2020-10-22
  2. Date Revised 2020-10-22
Further Info :

Pubmed ID

32053584

DOI: Digital Object Identifier

PMC7041302

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.